Navigation Links
Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
Date:5/10/2013

PARSIPPANY, N.J., May 10, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, today confirmed that Actavis has entered into early stage discussions with Warner Chilcott plc (Nasdaq: WCRX) regarding a potential combination of the two companies.  Actavis further stated that no agreement has been reached and it does not intend to issue further comment regarding its business development initiatives. 

About Actavis, Inc.Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. 

For press release and other company information, visit Actavis' Web site at http://www.actavis.com.

Forward-Looking Statement Statements contained in this press release that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Actavis' strategic initiatives, including a potential transaction with Warner Chilcott plc, are forward-looking statements. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actavis' performance, at times, will differ from its goals and expectations. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the inherent uncertainty associated with pending strategic transactions; the difficulty of predicting the timing and outcome of business and corporate development efforts and activities and risks that such activities may not result in a transaction being consummated; the ability to recognize the anticipated synergies and benefits of any transaction; and such other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis' Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the period March 31, 2013. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements. CONTACTS: Investors:Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20130124/NY47381LOGO )


'/>"/>
SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
2. Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
3. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
4. Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast
5. Former Clinton Deputy Solicitor General sheds light on flaws in Federal Trade Commissions case in FTC v. Actavis Inc.
6. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
7. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
8. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
9. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
10. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
11. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 6, 2016 ... of liver disorders along with rise in obesity ... drugs in the coming few years. The NASH ... last five years on account of rising number ... is a large, un-tapped market with no FDA ...
(Date:5/5/2016)... -- Replikins Ltd. today reported initial promising results in animal trials of its Zika vaccine ... ... ... ... on Pubmed. The analysis identified the highest gene Replikin Counts in Zika history back ...
(Date:5/5/2016)...  Endo International plc (NASDAQ: ENDP ... Lortie , President, U.S. Branded Pharmaceuticals, has decided ... appointment of a successor. Mr. Lortie joined Endo ... with responsibility for all strategic, commercial and operational ... development, commercial operations, managed markets, manufacturing, supply chain ...
Breaking Medicine Technology:
(Date:5/6/2016)... , ... May 06, 2016 , ... ... AsedaSciences® in an upcoming episode, airing third quarter 2016, via Discovery Channel. Dates ... of becoming a leader in optimized drug discovery through innovative cellular analysis. In ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... does to reduce fat areas around the body, is the most popular among ... results just released make perfect sense to cosmetic surgeon Dr. Richard Buckley, medical ...
(Date:5/6/2016)... Grants Pass, OR (PRWEB) , ... May 06, 2016 , ... ... the eyes. In other seasons, when the weather is too cold, dry or hot, ... weather, the eyes can actually absorb moisture from the surrounding air. There’s only one ...
(Date:5/6/2016)... ... May 06, 2016 , ... Online HR/benefits platforms offer a range ... game for traditional brokers and health plans. “ The Rapid Emergence of Online Benefits ... Atlantic Information Services, Inc. (AIS), will offer an accurate picture of online benefits today, ...
(Date:5/6/2016)... ... May 06, 2016 , ... From May 4 to 6, ... members the unique opportunity to learn more about Signia’s technology and the successful business ... “It is our priority to see practices succeed in this highly competitive industry,” said ...
Breaking Medicine News(10 mins):